Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.[Erratum appears in Cancer Immun. 2010 Feb 24;10:5 Note: Ritter, Erika [added]]

  • Yuan J
  • Page D
  • Ku G
 et al. 
  • 5


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each tumor in this patient being at a discrete stage in the process. The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters.

Author-supplied keywords

  • *Antibodies, Monoclonal/tu [Therapeutic Use]
  • *Antineoplastic Agents/tu [Therapeutic Use]
  • *Melanoma/dt [Drug Therapy]
  • *Melanoma/sc [Secondary]
  • *Skin Neoplasms/dt [Drug Therapy]
  • *Skin Neoplasms/pa [Pathology]
  • 0 (Antibodies, Monoclonal)
  • 0 (Antineoplastic Agents)
  • 6T8C155666 (ipilimumab)
  • Cell Count
  • Cell Separation
  • Female
  • Flow Cytometry
  • Humans
  • Immunohistochemistry
  • Lymphocytes/de [Drug Effects]
  • Melanoma/im [Immunology]
  • Middle Aged
  • Skin Neoplasms/im [Immunology]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • J Yuan

  • D B Page

  • G Y Ku

  • Y Li

  • Z Mu

  • C Ariyan

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free